

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

A North American Perspective: 2021 Update

ABSTRACT: A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing PCI require oral anticoagulation for the prevention of cardiac thromboembolism and dual antiplatelet therapy for the prevention of coronary thrombotic complications. The combination of oral anticoagulation and dual antiplatelet therapy substantially increases the risk of bleeding. Over the last decade, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention have been reported. Since the last update in 2018, several pivotal clinical trials in the field have been published. This document provides a focused updated of the 2018 recommendations. The group recommends that in patients with atrial fibrillation undergoing PCI, a non-vitamin K antagonist oral anticoagulant is the oral anticoagulation of choice. Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor should be given to all patients during the peri-PCI period (during inpatient stay, until time of discharge, up to 1 week after PCI, at the discretion of the treating physician), after which the default strategy is to stop aspirin and continue treatment with a P2Y₁₂ inhibitor, preferably clopidogrel, in combination with a non-vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone.

Dominick J. Angiolillo¹, MD, PhD
Deepak L. Bhatt², MD, MPH
Christopher P. Cannon, MD
John W. Eikelboom, MD
C. Michael Gibson, MD
Shaun G. Goodman³, MD
Christopher B. Granger⁴, MD
David R. Holmes⁵, MD
Renato D. Lopes⁶, MD, PhD
Roxana Mehran⁷, MD
David J. Moliterno, MD
Matthew J. Price, MD
Jacqueline Saw⁸, MD
Jean-Francois Tanguay, MD
David P. Faxon, MD

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

Key Words: anticoagulants ■ antiplatelets ■ atrial fibrillation ■ stents

© 2021 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

Atrial fibrillation (AF) is a highly prevalent arrhythmia that increases with age.¹ Up to 40% of patients with AF also have coronary artery disease (CAD), many of whom require revascularization.² Percutaneous coronary intervention (PCI) with stent implantation is the most common revascularization strategy for patients with CAD, and up to 10% of these patients have AF.²⁻⁴ The concomitant presence of these conditions represents a challenge in clinical practice, particularly with regard to their optimal antithrombotic treatment regimen.²⁻⁴ Most patients with AF require chronic oral anticoagulation (OAC) for the prevention of cardiac thromboembolism, whereas patients undergoing PCI require dual antiplatelet therapy (DAPT) with aspirin and a P2Y₁₂ inhibitor for the prevention of coronary thrombotic complications.⁵⁻⁷ The combination of OAC with DAPT, known as triple antithrombotic therapy (or simply triple therapy), substantially increases the risk of bleeding.⁴ Bleeding after PCI is associated with increased morbidity and mortality.⁸⁻¹⁰ These observations underscore the need to define antithrombotic strategies associated with a lower risk of bleeding while maintaining efficacy among patients with AF treated with PCI.

Since 2011, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention representing a consensus opinion of physicians from the United States and Canada have provided recommendations (2011, 2016, and 2018) on the antithrombotic treatment of patients with AF undergoing PCI.¹¹⁻¹⁴ The group has taken a pragmatic approach in making treatment recommendations for this high-risk patient population. After the most recent North American Consensus Statement on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, reported in 2018, results of pivotal clinical trials in the field have been published, prompting the need to update the document.

ANTITHROMBOTIC THERAPY IN PATIENTS WITH AF UNDERGOING PCI: RECENT UPDATES

New data since the 2018 recommendations include results of 2 additional randomized clinical trials (RCTs) conducted in patients with AF undergoing PCI as well as a number of secondary analyses, as described in the following. This new information has expanded our knowledge on the safety and efficacy of the 4 commercially available non-vitamin K antagonist oral anticoagulants (NOACs) that have been tested in dedicated RCTs, including rivaroxaban (PIONEER AF-PCI [A Study

Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention]), dabigatran (REDUAL-PCI [Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With Atrial Fibrillation That Undergo a PCI With Stenting]), apixaban (AUGUSTUS [An Open-Label, 2x2 Factorial, Randomized, Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention]), and edoxaban (ENTRUST-AF-PCI [Edoxaban Treatment vs Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention]).¹⁵⁻¹⁸ Results of these trials are described in detail elsewhere and summarized in Table 1.^{4,15-20}

In brief, the cumulative evidence from these studies, as also summarized in meta-analyses, supports the concept that a NOAC should be the OAC of choice.²¹⁻²⁵ Moreover, data from RCTs suggest that the combination of a NOAC and a single antiplatelet agent (SAPT), preferably a P2Y₁₂ inhibitor (clopidogrel has been the most studied), a strategy known as double antithrombotic therapy (or simply double therapy), should be used in preference to triple therapy.¹⁵⁻¹⁸ The use of aspirin in patients assigned to double therapy (ie, NOAC plus a P2Y₁₂ inhibitor) was limited to the peri-PCI period. Double therapy was associated with a large reduction in bleeding compared with triple therapy where aspirin is continued (ie, OAC, in particular a VKA, plus DAPT).¹⁵⁻²⁶ Although none of the individual RCTs was powered to assess major adverse ischemic events, there was no significant increase in thrombotic complications associated with double therapy.¹⁵⁻¹⁸ Advancements in stent designs leading to improved safety (ie, reduced stent thrombosis) and less dependence on the duration and intensity of DAPT have been instrumental toward improved outcomes.²⁷ However, insights from several trials as well as pooled data suggest the potential for an increase in thrombotic complications with double therapy, mostly confined to the first month after PCI.²⁵⁻²⁹ These observations have generated debate on the optimal timing of aspirin withdrawal in patients with AF undergoing PCI.

UPDATED FOCUSED CONSENSUS RECOMMENDATIONS

In our recommendations, we assume that patients with AF undergoing PCI have an indication for OAC in line with practice guidelines.^{5,6} It is important to underscore that DAPT is inferior to OAC for prophylaxis of thromboembolic events in patients with AF and accordingly should not be used as a mainstay

Table 1. Comparisons of Double Antithrombotic Therapy Versus Triple Antithrombotic Therapy in Trials of Non-Vitamin K Oral Antagonists in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Characteristics	PIONEER AF-PCI	REDUAL-PCI	AUGUSTUS	ENTRUST-AF-PCI
Year	2016	2017	2019	2019
Blinding	Open-label	Open-label	Open-label (NOAC vs VKA); placebo-controlled (SAPT vs DAPT)	Open-label
Patients, n	2124	2725	4614	1506
Intervention*	Rivaroxaban plus P2Y ₁₂ inhibitor for 12 months	Dabigatran plus P2Y ₁₂ inhibitor for 12 months	Apixaban or VKA plus P2Y ₁₂ inhibitor for 6 months	Edoxaban plus P2Y ₁₂ inhibitor for 12 months
Control	Warfarin plus DAPT for 1, 6, or 12 months	Warfarin plus DAPT for 1 (BMS) or 3 (DES) months	Apixaban or VKA plus DAPT for 6 months	VKA plus DAPT for 1 to 12 months
Primary outcome	Clinically relevant bleeding at 12 months	Major or CRNM bleeding through follow-up (mean 14 months)	Major or CRNM bleeding at 6 months	Major or CRNM bleeding at 12 months
Treatment effect for intervention vs control	HR, 0.59 (95% CI, 0.47–0.76); <i>P</i> <0.001 for superiority	HR, 0.72 (95% CI, 0.58–0.88); <i>P</i> <0.001 for noninferiority, <i>P</i> =0.002 for superiority (dabigatran 150 mg bid); HR, 0.52 (95% CI, 0.42–0.63); <i>P</i> <0.001 for noninferiority, <i>P</i> <0.001 for superiority (dabigatran 110 mg bid)	HR, 0.53 (95% CI, 0.45–0.63); <i>P</i> <0.001 for superiority	HR, 0.83 (95% CI, 0.65–1.05); <i>P</i> =0.001 for noninferiority, <i>P</i> =0.1154 for superiority

Doses of non-vitamin K antagonist oral anticoagulants were 15 mg once daily for rivaroxaban, 150 mg BID or 110 mg BID for dabigatran, 5 mg BID for apixaban (with dose reduction as per the instructions for use), and 60 mg once daily for edoxaban (with dose reduction as per the instructions for use). AUGUSTUS indicates An Open-Label, 2x2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention; BMS, bare metal stent; CRNM, clinically relevant nonmajor; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ENTRUST-AF-PCI, Edoxaban Treatment vs Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention; HR, hazard ratio; NOAC, non-vitamin K antagonist oral anticoagulant; PIONEER AF-PCI, A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention; REDUAL-PCI, Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With Atrial Fibrillation That Undergo a PCI With Stenting; SAPT, single antiplatelet therapy; and VKA, vitamin K antagonist.

*Interventions are shown for dual antiplatelet therapy groups only.

therapy.³⁰ The use of left atrial appendage closure devices represents an alternative to OAC for patients with high bleeding risk (HBR), with approval in the United States for patients deemed unsuitable for or unable to take long-term OAC.³¹ Indications for the use of left atrial appendage closure devices are beyond the scope of this document and are described elsewhere.³¹ Although patients undergoing PCI may have other medical conditions that require treatment with OAC (eg, mechanical valves), the recommendations provided in this document are specific to patients with AF. Moreover, patients enrolled in the RCTs that inform our recommendations were primarily treated with stents, and only a subset from one trial were medically managed patients with acute coronary syndrome (ACS), who also have an indication for DAPT.³² However, because outcomes were consistent irrespective of management (PCI versus medical therapy), we found it is reasonable to apply our recommendations to medically managed patients with ACS.

In the sections that follow, we provide consensus recommendations for management of patients with AF undergoing PCI, including key procedural (before, during, and after) approaches and antithrombotic management. A summary of these procedural considerations is provided in Figure 1. We refer to other documents for more extensive background description on the topic.^{4,20,33} A summary of key changes since the 2018 update is provided in Table 2.

Procedural Considerations

Preprocedural

Clinicians should carefully evaluate the risk of bleeding and thrombotic complications in all patients undergoing PCI, particularly those with AF. Selection of patients for PCI should take into consideration the absolute need for antiplatelet therapy postprocedure, which markedly increases the risk of bleeding when added to OAC. Discussing appropriateness criteria for PCI is beyond the scope of this article and is described elsewhere but should be taken into strong consideration.³⁴ The consensus of this group is that, whenever possible (ie, elective/nonemergent procedures), a brief period of washout from the effects of an OAC is preferable when undergoing an invasive procedure. The rationale for a washout is to reduce the risk of potential bleeding complications among patients who may require femoral vascular access or resulting from excess anticoagulation during the interventional procedure. Timing of discontinuation of OAC should take into account the timing of the procedure to minimize the duration of treatment interruption. The rapid offset of action of the NOACs has simplified this approach: interruption of therapy for 24 hours (or 48 hours for patients on dabigatran with impaired renal function) is sufficient in most cases.³⁵ For patients on a VKA, this consensus group recommends an international normalized ratio (INR) ≤ 2.0 when using a radial approach and ≤ 1.5 when using a femoral approach. After discontinuation of OAC,




Figure 1. Pragmatic algorithm for the management of patients with atrial fibrillation requiring oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI).

APT indicates antiplatelet therapy; DES, drug-eluting stent; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor; RCT, randomized, controlled trial; and VKA, vitamin K antagonist.

patients presenting with an ACS with planned invasive management should receive parenteral anticoagulation according to usual practice, which is not required for patients with stable CAD. The performance of invasive procedures without withholding OAC should generally be reserved for urgent or emergency procedures.

Intraprocedural

The radial approach is the preferred choice for vascular access to minimize bleeding.³⁶ Several intraprocedural parenteral antithrombotic agents are available, although none has been directly compared in patients with AF undergoing PCI. Unfractionated heparin is the most commonly used intraprocedural anticoagulant and remains the agent of choice in this setting, with dosing titrated to target recommended activated clotting times. Bivalirudin has been shown to be associated with a reduction in bleeding complications and may be of value in patients with ACS undergoing PCI via a femoral approach who are at increased bleeding risk.^{37–39} Bivalirudin is the agent of choice for patients with heparin-induced thrombocytopenia and should also be considered in circumstances of heparin shortage. The North American uptake of enoxaparin for PCI has been limited, but it is important to emphasize that switching from unfractionated heparin to enoxaparin (and vice versa) may increase the risk of bleeding.⁴⁰ Parenteral antiplatelet agents (ie, glycoprotein IIb/IIIa inhibitors and cangrelor) should be reserved for selected patients at high risk for thrombotic complications or for

bailout situations.⁴¹ Cangrelor may be a more desirable agent if prompt and potent platelet inhibition is needed given its pharmacodynamic profile with rapid offset of action as well as data that suggest that it is possibly associated with a lower risk of bleeding compared with a glycoprotein IIb/IIIa inhibitor.^{41–43} New-generation metallic drug-eluting stents have a more favorable safety and efficacy profile over earlier-generation drug-eluting stents and bare metal stents, and some of these novel stent platforms have been specifically tested in patients requiring OAC.^{27,44,45} Accordingly, commercially available new-generation metallic drug-eluting stents should be the devices of choice. Patients should resume OAC after PCI before or at hospital discharge once hemostasis is fully obtained, there is no evidence of ongoing periprocedural bleeding complications, and no further in-hospital interventions are anticipated. The rapid onset of action of a NOAC eliminates the need for a parenteral anticoagulant agent after PCI. In patients resuming treatment with a VKA, our consensus-based suggestion is for clinicians to consider continuing treatment with a parenteral agent until an INR is at least 1.8 among patients at high stroke risk, although there are no data to support the efficacy of this approach.

Postprocedural

Patients should ideally be re-evaluated within 1 to 2 weeks of PCI by their cardiologist or interventional cardiologist to assess adherence and determine whether any adjustments in antithrombotic treatment regimens

Table 2. Key Changes Between 2018 and 2020 North American Consensus on Antithrombotic Management of Patients With Atrial Fibrillation (AF) Undergoing Percutaneous Coronary Intervention (PCI)

	2018 Consensus	2021 Consensus update
Definition of high bleeding risk	According to ACC/AHA DAPT guidelines	According to ARC-HBR criteria
Definition of high thrombotic risk	According to ACC/AHA DAPT guidelines	ACS, previous stent thrombosis while on antiplatelet treatment, and complex PCI (3 vessels treated, ≥ 3 stents implanted, ≥ 3 lesions treated, bifurcation with 2 stents implanted, total stent length >60 mm, surgical bypass graft or chronic total occlusion as target lesions, atherectomy device use, or left main PCI)
Definition of high ischemic risk	According to ACC/AHA DAPT guidelines	Previous myocardial infarction, multivessel CAD, polyvascular disease, diabetes mellitus, chronic kidney disease, heart failure
Definition of peri-PCI period (ie, timing of mandatory aspirin)	Up to hospital discharge	During inpatient stay, until time of discharge (generally occurring 1 to 2 days after PCI), up to 1 week after PCI, at the discretion of the treating physician
Recommendations for medically managed ACS	NA	Consistent with recommendations for patients undergoing PCI

ACC indicates American College of Cardiology; ACS, acute coronary syndrome; AF, atrial fibrillation; AHA, American Heart Association; ARC-HBR, Academic Research Consortium for High Bleeding Risk; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; NA, not applicable; and PCI, percutaneous coronary intervention.

are needed. Key issues include defining timing of stopping of aspirin (if not yet discontinued), evaluating INR control, particularly in patients newly started on a VKA, and monitoring of renal function in patients treated with a NOAC. Patients should be counseled not to stop therapy due to nuisance bleeding or bruising, but rather to contact their physician. Additional strategies to reduce the risk of bleeding should be considered, including optimization of blood pressure control, use of proton pump inhibitors, and avoidance of nonsteroidal anti-inflammatory drugs.^{46,47}

Definition of Bleeding and Thrombotic Risk

Defining the risk of developing a bleeding or thrombotic complication in a patient undergoing PCI is of essential importance in defining the intensity and duration of antithrombotic therapy. Although intensive and prolonged antithrombotic treatment regimens reduce the risk of thrombotic complications, this occurs at the expense of increased bleeding.^{9,20} The ever-growing evidence on the adverse prognosis, including increased mortality, associated with bleeding after PCI has prompted investigations aimed at reducing bleeding while preserving efficacy, such as shortening DAPT duration, de-escalating P2Y₁₂ potency, and using aspirin-free approaches.^{9,20,27,48,49} Defining the optimal antithrombotic regimen in the PCI setting is further complicated by the fact that risk factors for bleeding and thrombotic complications frequently overlap.⁵⁰ This may partly explain why these risk scores are only modestly predictive.⁵⁰ As recommended in practice guidelines, bleeding risk scores (eg, HAS-BLED) can be used to identify potentially modifiable risk factors for bleeding (eg, uncontrolled hypertension, suboptimal INR control on VKA therapy,

and concomitant use of excess alcohol or nonsteroidal anti-inflammatory drugs) and not to define whether a patient should be treated with OAC, because patients with high scores derive similar or greater ischemic benefit from treatment compared with patients with lower scores.^{5,6} Although other risk scores (eg, PRECISE-DAPT) have been able to identify patients with AF undergoing PCI who are at increased bleeding risk, these have not been prospectively validated in this setting.^{51,52} Accordingly, this group consensus cannot recommend the use of a specific risk score to make decisions on treatment. Instead, the use of qualitative or semiquantitative approaches, together with clinical judgment, are recommended to assist practitioners with defining the bleeding and thrombotic risk of an individual patient.

Data suggest that when both ischemic and bleeding risk factors are present, the risk factors for bleeding are more impactful on clinical outcomes.⁵³ Applying this concept to patients with AF undergoing PCI is challenging given that the OAC treatment itself is a major criterion for HBR according to the Academic Research Consortium definitions.¹⁰ Nevertheless, this group consensus finds the Academic Research Consortium HBR definition useful to inform clinicians of criteria beyond OAC treatment that further affect the risk of bleeding. This is in line with recent findings not only validating the Academic Research Consortium HBR definitions but also showing a progressive increase in bleeding risk with incremental risk criteria.^{54,55} Accordingly, a patient with HBR is identified as having 1 major (other than use of OAC) or 2 minor criteria according to Academic Research Consortium definitions (Table 3).¹⁰

Most thrombotic complications reported in the available RCTs occurred early (ie, within the first month after PCI).^{15–19} However, analysis of RCTs has not identified independent predictors of thrombotic complications and available data suggest that the benefit of double

Table 3. Definition of High Bleeding Risk According to Academic Research Consortium Criteria

Major	Minor
Anticipated use of long-term oral anti-coagulation*	Age ≥75 years
Severe or end-stage CKD (eGFR <30 mL/min)	Moderate CKD (eGFR 30 to 59 mL/min)
Hemoglobin <11 g/dL	Hemoglobin 11 to 12.9 g/dL for men and 11 to 11.9 g/dL for women
Spontaneous bleeding requiring hospitalization or transfusion in the past 6 months or at any time, if recurrent	Spontaneous bleeding requiring hospitalization or transfusion within the past 12 months not meeting the major criterion
Moderate or severe baseline thrombocytopenia† (platelet count <100×10 ⁹ /L)	Long-term use of oral NSAIDs or steroids
Chronic bleeding diathesis	Any ischemic stroke at any time not meeting the major criterion
Liver cirrhosis with portal hypertension	—
Active malignancy‡ (excluding non-melanoma skin cancer) within the past 12 months	—
Previous spontaneous ICH (at any time)	—
Previous traumatic ICH within the past 12 months	—
Presence of a bAVM	—
Moderate or severe ischemic stroke§ within the past 6 months	—
Nondeferrable major surgery on DAPT	—
Recent major surgery or major trauma within 30 days before PCI	—

Adapted from Urban et al¹⁰ with permission. bAVM indicates brain arteriovenous malformation; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; ICH, intracranial hemorrhage; NSAID, nonsteroidal anti-inflammatory drug; and PCI, percutaneous coronary intervention.

*Excludes vascular protection doses.

†Baseline thrombocytopenia is defined as thrombocytopenia before PCI.

‡Active malignancy is defined as diagnosis within 12 months or ongoing requirement for treatment (including surgery, chemotherapy, or radiotherapy).

§National Institutes of Health Stroke Scale score ≥5.

therapy over triple therapy is consistent irrespective of thrombotic risk.^{28,29,56–59} Nevertheless, there are a number of well-established factors associated with the risk of thrombotic complications after PCI. Patients presenting with an ACS have an increased risk of thrombotic complications, which is highest within the first month after PCI and then diminishes over time.^{56,60} Patients with a previous stent thrombosis while on antiplatelet therapy are also at increased risk of a thrombotic recurrence.⁶¹ Procedural characteristics (ie, PCI complexity) are also closely associated with the early risk of thrombotic complications after PCI.^{57,62,63} Accordingly, this consensus opinion recognizes that acute clinical presentations, previous stent thrombosis while on antiplatelet therapy, and complex PCI can be considered as factors that can help define the risk of thrombotic

events more likely to occur early after PCI (Table 4). Patients with certain risk factors (eg, previous myocardial infarction, multivessel CAD, polyvascular disease, diabetes mellitus, chronic kidney disease, heart failure) are more likely to undergo complex PCI and remain at increased ischemic risk.⁶⁴ These factors are associated with long-term ischemic recurrences and can be considered when making assessments on long-term antithrombotic management (Table 4).

Oral Antithrombotic Therapy

The large number of antithrombotic agents that are now available allows for multiple combinations of OAC and antiplatelet regimens.⁴ Selection of the antithrombotic regimen should involve a shared decision-making process taking into account physician experience, patient preferences, access, and cost.

Oral Anticoagulation

Choice of Agent and Duration of Therapy

In line with our previous recommendations, now reinforced with recent clinical trial data, this consensus group recommends that, in the absence of contraindications, a NOAC should be preferred over a VKA in patients with AF undergoing PCI. This recommendation stems from the consistent reduction in bleeding complications with a NOAC, including intracranial hemorrhage, without an apparent trade-off in efficacy.^{21–24} In line with general guidelines on the use of OAC in patients with AF, the lack of head-to-head comparisons between NOACs does not allow us to recommend one agent over another.^{5,6} The selection of a specific agent and dose should take into consideration aspects of the trial design in which a given NOAC was tested that best

Table 4. Definition of High Thrombotic and Ischemic Risk

High thrombotic risk (early events)	High ischemic risk (long-term events)
Acute coronary syndrome	Previous myocardial infarction
Previous stent thrombosis while on antiplatelet treatment	Multivessel coronary artery disease
PCI complexity	Polyvascular disease
3 vessels treated	Diabetes mellitus
≥3 stents implanted	Chronic kidney disease
≥3 lesions treated	Heart failure
Bifurcation with 2 stents implanted	
Total stent length >60 mm	
Surgical bypass graft PCI	
Chronic total occlusion PCI	
Atherectomy device use	
Left main PCI	

PCI indicates percutaneous coronary intervention.

matches the profile of the patient being treated.^{15–18} The specific trial results can also provide information on the magnitude of benefit when choosing one agent compared with VKA.^{15–18} PIONEER AF-PCI (A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention) was the only trial that excluded patients with a previous cerebrovascular event.¹⁵ ENTRUST-AF-PCI (Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) was the only trial that did not show superiority in bleeding reduction of a NOAC-based double therapy regimen compared with a VKA, although noninferiority was met.¹⁸ AUGUSTUS (An Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), the largest trial, was the only trial to test aspirin in a placebo-controlled fashion and the only trial that showed lower bleeding with the NOAC (apixaban) versus VKA in a direct comparison using a factorial design.¹⁷ Patient access to individual NOACs based on availability and cost may also be a driving factor in the decision-making process. Availability of a NOAC in a generic formulation may facilitate broader access. Patients may also have a preference for NOACs that are administered once daily (ie, rivaroxaban, edoxaban) versus twice daily (ie, dabigatran, apixaban). We suggest avoiding switching between NOACs in patients who have already been adherent without complications on a specific agent at a dose that has been approved for stroke prevention in AF. On the other hand, in the absence of contraindications and if drug access is not a limiting factor, patients on a VKA before PCI should consider switching to a NOAC in light of the better safety profile.⁶⁵ A VKA remains the only indicated OAC for patients with moderate to severe mitral stenosis, a mechanical prosthetic heart valve, left ventricular thrombus, or other hematologic reasons (eg, antiphospholipid syndrome).^{5,6} Although there are emerging data on the safety of a NOAC in patients with severe renal dysfunction, these patients were excluded from trials of patients with AF undergoing PCI.^{15–18} Unless contraindicated, the duration of OAC treatment in patients with AF should be lifelong.^{5,6}

Dosing Regimen

In real-world practice, NOAC dosing regimens lower than those proven to be effective for stroke prevention are commonly used because of bleeding concerns, particularly because bleeding risk is enhanced with concomitant antiplatelet therapy.^{66,67} However, dosing regimens lower than those proven to be efficacious in RCTs of AF should be avoided, unless specifically tested. The

dosing regimen should also take into consideration adjustments according to renal function or other instructions for use. The NOAC dosing regimens tested in the randomized trials of patients with AF undergoing PCI are summarized in Table 1.^{15–19} With the exception of PIONEER AF-PCI, in all RCTs of patients with AF undergoing PCI the dosing regimens of NOACs tested were those previously established in efficacy trials for stroke prevention (Table 1 in the Data Supplement).^{4–6,15–19} For patients with AF who are treated with a VKA and concomitant antiplatelet therapy, the INR should be targeted to the lower end of the therapeutic range (eg, 2.0 to 2.5).⁶⁸

In PIONEER AF-PCI, 2 dosing regimens of rivaroxaban (both lower than previously established for stroke prevention in AF trials) were tested: 15 mg once daily (10 mg once daily if creatinine clearance was 30 to 50 mL/min) with a P2Y₁₂ inhibitor and 2.5 mg twice daily with DAPT. These doses are not approved in North America for stroke prevention and were chosen based on safety investigations evaluating their use in combination with different antiplatelet regimens.^{15,69} This consensus suggests that rivaroxaban 15 mg could be used in patients receiving double therapy (ie, in combination with SAPT) as tested in PIONEER AF-PCI.¹⁵ Other dosing regimens, particularly triple therapy with rivaroxaban 20 mg plus DAPT, known to be associated with unacceptably high rates of bleeding should be avoided.⁷⁰

In REDUAL-PCI (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With Atrial Fibrillation That Undergo a PCI With Stenting), 2 dosing regimens of dabigatran were used: 150 mg twice daily with SAPT and 110 mg twice daily with a P2Y₁₂ inhibitor.¹⁶ Elderly patients (≥80 years of age; ≥70 years of age in Japan) randomized outside the United States were treated with dabigatran 110 mg twice daily. Although the 150 mg and 110 mg doses are both approved for stroke prevention in patients with AF by most countries' drug-regulating authorities, the 110 mg regimen is not approved by the US Food and Drug Administration. In light of the numeric increase, albeit not statistically significant, of ischemic events among patients treated with dabigatran 110 mg, it is reasonable to prefer a 150 mg dosing regimen in patients considered to be at higher thrombotic risk, while a 110 mg regimen may be preferred in patients with HBR.¹⁶

In AUGUSTUS, the largest of the available RCTs, apixaban was administered at a regimen of 5 mg twice daily (2.5 mg twice daily if ≥2 of the following dose reduction criteria were met: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) with a P2Y₁₂ inhibitor or DAPT.¹⁷ This regimen is in line with that approved for stroke prevention in patients with AF by most drug-regulating authorities, including the US Food and Drug Administration. Of note, AUGUSTUS was the only trial that by nature of its 2×2 factorial design directly

compared a NOAC (ie, apixaban) versus VKA in patients treated with a dual versus triple (aspirin versus placebo) therapy regimen and the only trial to test aspirin in a placebo-controlled fashion.

In the ENTRUST-AF-PCI trial, edoxaban was administered at a dose of 60 mg once daily (30 mg once daily for patients with creatinine clearance 15 to 50 mL/min, body weight ≤ 60 kg, or concurrent use of specific potent P-glycoprotein inhibitors [cyclosporine, dronedarone, erythromycin, or ketoconazole]) with a P2Y₁₂ inhibitor.¹⁸ This regimen is consistent with that approved for stroke prevention in patients with AF by most drug-regulating authorities, although the US Food and Drug Administration has restricted the approval of edoxaban to patients with a creatinine clearance <95 mL/min (because higher clearance rates were associated with greater stroke risk as compared with patients receiving VKA).

Antiplatelet Therapy

Choice of Agent

DAPT with aspirin and a P2Y₁₂ inhibitor is the cornerstone of treatment for the prevention of thrombotic complications in patients undergoing PCI.⁴ All patients undergoing PCI, even those with AF requiring OAC, should be treated with aspirin in the peri-PCI period. After a 325 mg loading dose administration (in aspirin-naïve patients), the maintenance dose of aspirin should be 75 to 100 mg/d.⁴ Clopidogrel is the P2Y₁₂ inhibitor of choice because this was used in most ($\approx 88\%$) patients (at the discretion of the treating physician) enrolled in trials of patients with AF undergoing PCI concomitantly treated with an OAC (Table 1).^{15–19} Accordingly, clopidogrel should be administered as a 600 mg loading dose followed by a 75 mg daily maintenance dose. The more potent P2Y₁₂ receptor antagonists, prasugrel and ticagrelor, are both approved for use in patients with ACS, with recent approval of ticagrelor in patients with CAD with high ischemic risk as well, with lower rates of cardiovascular events, including stent thrombosis, and higher rates of bleeding than clopidogrel.^{71–73} Data on the combination of prasugrel with a NOAC are limited. In one small observational study, triple therapy using a VKA, aspirin, and prasugrel was associated with a 4-fold higher rate of bleeding.⁷⁴ The use of prasugrel in the 4 pivotal RCTs was also low (1.3% in PIONEER AF-PCI, 1.1% in AUGUSTUS, 0.5% in ENTRUST-AF-PCI, and excluded in REDUAL-PCI). Accordingly, prasugrel should be avoided in patients concomitantly treated with an OAC. The faster offset of action of ticagrelor (3 to 5 days) compared with prasugrel (7 to 10 days) makes it preferable if more potent P2Y₁₂ inhibition is required.⁶⁰ Although data with ticagrelor are also limited, its use in the 4 pivotal RCTs was higher than prasugrel (4.3% in PIONEER AF-PCI, 12.0% in REDUAL-PCI, 6.2% in AUGUSTUS, and 7.0% in ENTRUST-AF-PCI).

Although the safety and efficacy findings were consistent with the overall trial results, bleeding rates were higher with more potent P2Y₁₂ inhibitors.^{15–19,56,75} Therefore, it cannot be excluded that larger patient cohorts treated with potent P2Y₁₂ inhibitors could have significantly affected the safety outcomes. Moreover, the selection of P2Y₁₂ inhibitor type was not randomized and was at the discretion of the treating physician. In light of these considerations, the use of a more potent P2Y₁₂ inhibitor (ie, ticagrelor) should be reserved only for patients at highest thrombotic risk (eg, patients with ACS undergoing complex PCI) and acceptable bleeding risk. Ticagrelor should be administered as a 180 mg loading dose and 90 mg twice daily maintenance dose. Although a lower maintenance dose regimen (ie, 60 mg twice daily) is available for clinical use and has been shown to provide more potent and consistent antiplatelet effects than clopidogrel after PCI, this has yet to be tested together with OAC.^{76,77} When ticagrelor is combined with OAC, aspirin use should generally be discontinued after the peri-PCI period.

Although studies have shown that a considerable number of patients may have impaired clopidogrel response and may be at increased risk of thrombotic complications, to date there are no outcome studies that have evaluated the use of alternate P2Y₁₂ inhibitors in patients with AF undergoing PCI based on results of pharmacodynamic or genetic determinants.⁷⁸ The usefulness of platelet function or genetic testing to guide the selection of P2Y₁₂-inhibiting therapy goes beyond the scope of this article and is discussed elsewhere.⁷⁸

Strategy (Double Versus Triple Antithrombotic Therapy)

The available evidence demonstrates a reduction in bleeding complications with the use of double compared with triple therapy.^{4,15–26,79} Although none of the RCTs were powered to assess major adverse ischemic events or stent thrombosis, there was no significant increase in ischemic events associated with double therapy in the individual trials.^{15–18} However, results of some of the available meta-analyses suggest the potential for an increase in thrombotic complications with double therapy.^{25,26} In all trials, the use of aspirin was mandatory in the peri-PCI period, indicating that all patients were exposed to triple therapy.^{15–18} However, the time from PCI to randomization varied among trials. It is assumed that patients were likely to have been treated with aspirin until randomization. This time frame ranged from 0 to 14 days after PCI across trials. In particular, in 3 of the 4 RCTs (PIONEER AF-PCI, REDUAL-PCI, and ENTRUST-AF-PCI), aspirin was used on average for 1 to 2 days after PCI, and in the other RCT (AUGUSTUS), for 6 days.^{15–18} Details on the duration of aspirin before randomization is provided in Table 5.^{15–18} Accordingly, we refer to the time frame during which aspirin therapy

Table 5. Timing of Randomization After Percutaneous Coronary Intervention (PCI) in the Pivotal Randomized Trials of Patients With Atrial Fibrillation Undergoing PCI

Timing of randomization	PIONEER AF-PCI	REDUAL-PCI	AUGUSTUS	ENTRUST-AF-PCI
Timing of randomization from PCI procedure	Within 3 days	Within 5 days	Within 14 days	Within 5 days
Median time (interquartile range) to randomization, d	1 (1 to 2)	1 (1 to 2)	6 (3 to 10)	1.9 (0.9 to 3.2)
Mean time (SD) to randomization, d	1.62 (7.98)	1.6 (1.2)	6.6 (4.19)	2.2 (1.4)

AUGUSTUS indicates An Open-Label, 2x2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention; ENTRUST-AF-PCI, Edoxaban Treatment vs Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention; PIONEER AF-PCI, A Study Exploring Two Strategies of Rivaroxaban and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention; and REDUAL-PCI, Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With Atrial Fibrillation That Undergo a PCI With Stenting.

was maintained in the pivotal trials (Table 5) to define the peri-PCI period in our consensus recommendations. In line with these considerations, this group recommends as the default strategy the use of aspirin during the peri-PCI period, defined as during inpatient stay, until time of discharge (generally occurring 1 to 2 days after PCI), and up to 1 week after PCI, at the discretion of the treating physician, before lessening to double therapy (Figure 2).^{15–18} In all trials, the efficacy outcomes were consistent across all predefined subgroups, including those at increased thrombotic risk.^{15–18,28,29,56–59} It is important to consider that, given the irreversible binding of aspirin to the cyclooxygenase-1 enzyme, residual platelet inhibitory effects induced by aspirin persist for the lifespan of the affected platelet (7 to 10 days).⁴

In patients treated with OAC undergoing PCI, bleeding complications occur early and accrue over time.^{4,20} Therefore, in patients with additional risk factors for bleeding (Table 3), the duration of aspirin therapy should not go beyond the peri-PCI period as described above, irrespective of their thrombotic risk. However, the first month after PCI coincides with the highest risk period for the occurrence of thrombotic complications.^{25–29} Therefore, given that there is potential for an increase in thrombotic complications with double therapy during the first month in patients at high thrombotic risk (Table 4), in the absence of adjunctive major criteria for bleeding (Table 3), it is reasonable to continue aspirin for up to 1 month after PCI. The AUGUSTUS trial showed that the use of aspirin immediately and for up to 30 days results in an equal tradeoff between an increase in severe bleeding and a reduction in severe ischemic events.²⁹ After 30 days, aspirin continues to increase bleeding without significantly reducing ischemic events. Landmark analysis assessments from other trials to define the trade-off between ischemic and bleeding events are ongoing. Nevertheless, these data are derived from post hoc assessments and there have not been randomized studies to date that have specifically assessed the clinical impact of aspirin therapy for 1 month after PCI. Extending aspirin therapy beyond 1 month after PCI is not recommended (Figure 2).

Duration of Antiplatelet Therapy

In line with previous recommendations, the default duration of the dual antithrombotic regimen and hence the timing of discontinuation of SAPT for most patients is 1 year (Figure 2).⁴ This is based on the lack of evidence that continuing antiplatelet therapy provides any additional ischemic benefit but increases bleeding.^{80–82} This evidence now expands to patients treated with a NOAC, as recently shown in the AFIRE trial (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease), which was stopped early because of increased mortality in patients concomitantly treated with single antiplatelet therapy compared with rivaroxaban monotherapy, which was noninferior on efficacy outcomes and associated with reduced bleeding.⁸² It may be argued that patients at enhanced risk for ischemic recurrences (eg, previous stent thrombosis) may have been excluded from this trial and hence the net benefit associated with maintaining long-term SAPT may vary according to the thrombotic and bleeding risk profiles of the individual patient. Our group consensus is that continuation of SAPT (in addition to OAC) beyond 1 year should be considered only in patients at high risk for ischemic recurrences and without adjunctive criteria for bleeding risk, although even then the risk may outweigh the benefit. When used, the choice of SAPT to use after 1 year (aspirin or clopidogrel) is at the discretion of the treating physician, although it appears to be reasonable to maintain the same antiplatelet drug that the patient was already taking rather than switching. On the other hand, in patients at low ischemic risk as well as those at high risk for bleeding, it is reasonable to discontinue SAPT at 6 months after PCI. After discontinuation of SAPT, OAC should be continued at full stroke prevention doses. Therefore, if a reduced-dose regimen of rivaroxaban was used, in line with PIONEER AF-PCI, it is important to resume the established stroke prevention dose (20 mg once daily; 15 mg once daily in patients with creatinine clearance 15 to 50 mL/min) after suspension of antiplatelet therapy.

AF patients undergoing PCI—2021 North American Consensus			
Time from PCI	Default strategy	Patients at high ischemic/thrombotic and low bleeding risk	Patients at low ischemic/thrombotic or high bleeding risk
Peri-PCI	Triple Therapy (OAC + DAPT)	Triple Therapy (OAC + DAPT)	Triple Therapy (OAC + DAPT)
1 month	Double Therapy up to 12 months (OAC + P2Y ₁₂ inhibitor)	Triple Therapy up to 1 month (OAC + DAPT)	Double Therapy up to 6 months (OAC + P2Y ₁₂ inhibitor)
3 months		Double Therapy up to 12 months (OAC + P2Y ₁₂ inhibitor)	
6 months			
12 months			
>12 months	OAC alone	OAC alone	OAC alone

Peri-PCI period: inpatient stay until time of discharge or a few days longer, up to 1 week post-PCI.

OAC: prefer a NOAC over VKA if no contraindications.

Clopidogrel is the P2Y₁₂ inhibitor of choice; ticagrelor may be considered in patients at high thrombotic and acceptable bleeding risks; avoid prasugrel.

Continuation of antiplatelet therapy in adjunct to OAC beyond one-year should be considered only for select patients with high risk for ischemic recurrences and low bleeding risk.

Figure 2. Management of antiplatelet therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) treated with an oral anticoagulant: 2018 North American Consensus Update.

A double-therapy regimen, consisting of oral anticoagulant therapy (OAC) plus a P2Y₁₂ inhibitor, should be considered for most patients immediately after the peri-PCI period (Default Strategy). Aspirin should be used during the peri-PCI period, defined as inpatient stay until time of discharge, generally 1 to 2 days after PCI, and in some patients continued for 1 week after PCI. A non-vitamin K antagonist oral anticoagulant (NOAC) should be preferred over a vitamin K antagonist (VKA) unless contraindicated. Clopidogrel is the P2Y₁₂ inhibitor of choice; ticagrelor may be an alternative in patients with high thrombotic and acceptable bleeding risk; prasugrel should be avoided. It is reasonable to continue aspirin for up to 1 month after PCI (ie, triple therapy) in patients at high thrombotic risk and who have an acceptable risk of bleeding. Extending aspirin therapy beyond 1 month after PCI is not recommended. P2Y₁₂-inhibiting therapy should be discontinued at 1 year in most patients; earlier discontinuation (eg, 6 months) can be considered in patients at low ischemic or high bleeding risk; continuation of antiplatelet therapy beyond 1 year should be considered only in select patients with high risk for ischemic recurrences and low bleeding risk. DAPT indicates dual antiplatelet therapy.

NORTH AMERICAN CONSENSUS ON THE MANAGEMENT OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH AF UNDERGOING PCI: SUMMARY OF THE 2021 FOCUSED UPDATE

This consensus group recommends that for patients with AF requiring the use of OAC and who are treated with stents, DAPT with aspirin and a P2Y₁₂ inhibitor should be given to all patients during the peri-PCI period, after which the default strategy is to stop aspirin and continue treatment with a P2Y₁₂ inhibitor in combination with a NOAC (ie, double therapy). We recommend as the default strategy the use of aspirin during inpatient stay until time of discharge (generally occurring 1 to 2 days after PCI) up to 1 week after PCI at the discretion of the

treating physician before lessening to double therapy. In patients with additional risk factors for bleeding, the duration of aspirin therapy should not go beyond the peri-PCI period. However, given the observation that there is a potential for an increase in thrombotic complications with double therapy during the first month, in patients deemed to be at high thrombotic risk and who have an acceptable risk of bleeding, it is reasonable to continue aspirin for up to 1 month after PCI. Nevertheless, extending aspirin therapy beyond 1 month after PCI is not recommended. Clopidogrel remains the P2Y₁₂ inhibitor of choice, but ticagrelor may be considered in selected patients, particularly those at high thrombotic risk and acceptable bleeding risk. In the absence of contraindications, a NOAC should be preferred over a VKA. The dosing regimen of a NOAC should be that recommended for thromboembolic protection in patients with AF; the use of lower doses is not recommended,

unless specifically studied in randomized trials (ie, rivaroxaban 15 mg). Where different therapeutic dosing options (ie, dabigatran 110 and 150 mg) are available, the intensity of anticoagulant treatment should be tailored according to the bleeding and thrombotic risk profile of the patient. Discontinuation of P2Y₁₂-inhibiting therapy at 1 year should be considered for most patients who should maintain treatment on stroke prevention doses of OAC. However, in patients at low thrombotic risk as well as those at high risk for bleeding, it is reasonable to discontinue P2Y₁₂-inhibiting therapy at 6 months after PCI. Continuation of antiplatelet therapy in adjunct to OAC beyond 1 year should be reserved only for select patients with high risk for ischemic recurrences and low bleeding risk.

ARTICLE INFORMATION

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.050438>.

Correspondence

Dominick J. Angiolillo, MD, PhD, University of Florida College of Medicine—Jacksonville, 655 West 8th Street, Jacksonville, FL 32209. Email dominick.angiolillo@jax.ufl.edu

Affiliations

Division of Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.). Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B., C.P.C., D.P.F.). Department of Medicine, Population Health Research Institute, Thrombosis & Atherosclerosis Research Institute, Hamilton, Canada (J.W.E.). Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.). St Michael's Hospital, University of Toronto, Canada (S.G.G.). The Canadian Heart Research Centre, Toronto, Canada (S.G.G.). Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.). Duke Clinical Research Institute, Duke University, Durham, NC (C.B.G., R.D.L.). Division of Cardiology, Mayo Clinic, Rochester, MN (D.R.H.). The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (R.M.). Division of Cardiovascular Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.). Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA (M.J.P.). Division of Cardiology, Vancouver General Hospital, University of British Columbia, Canada (J.S.). Department of Medicine, Montreal Heart Institute, Université de Montréal, Canada (J.-F.T.).

Disclosures

Dr Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; has received payments for participation in review activities from CeloNova and St Jude Medical; and his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Dr Bhatt discloses the following relationships: advisory board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; chair: American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for PORTICO [Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial], funded by St Jude Medical, now Abbott), Cleveland Clinic (including for the EXCEED trial [EXCEED: Centera THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic

Stenosis], funded by Edwards), Contego Medical (Chair, PERFORMANCE-II [Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System]), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial [Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation], funded by Daiichi-Sankyo), and Population Health Research Institute; honoraria: American College of Cardiology (Senior Associate Editor, *Clinical Trials and News*, ACC.org; Vice-Chair, American College of Cardiology Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; REDUAL-PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome] executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, *Harvard Heart Letter*), Duke Clinical Research Institute (clinical trial steering committees, including for PRONOUNCE [A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease], funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, *Journal of Invasive Cardiology*), *Journal of the American College of Cardiology* (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS [Cardiovascular Outcomes for People Using Anticoagulation Strategies] operations committee, publications committee, steering committee, and US national coleader, funded by Bayer), Slack Publications (Chief Medical Editor, *Cardiology Today's Intervention*), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); other: *Clinical Cardiology* (Deputy Editor), National Cardiovascular Data Registry ACTION Registry Steering Committee (Chair), VA Clinical Assessment, Reporting and Tracking Program Research and Publications Committee (Chair); research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company; royalties: Elsevier (Editor, *Cardiovascular Intervention: A Companion to Braunwald's Heart Disease*); site coinvestigator: Biotronik, Boston Scientific, CSL, St Jude Medical (now Abbott), and Svelte; trustee: American College of Cardiology; and unfunded research: FlowCo, Merck, Novo Nordisk, and Takeda. Dr Cannon reports research grants from Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Merck, and Pfizer; and consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, Eli Lilly, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, Sanofi, and Rhoshan. Dr Eikelboom reports honoraria and/or research support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Janssen, Pfizer, and Servier. Dr Faxon reports support from Boston Scientific, Medtronic, HighLife Medical, Otsuka, Surmodics, and Conformal. Dr Gibson receives research funds from Janssen and Johnson & Johnson and consulting funds from Janssen, Johnson & Johnson, and Bayer. Dr Goodman reports research grant support (eg, steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (eg, advisory boards) from: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk A/C, Pfizer, Regeneron, Sanofi, and Servier; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Center and MD Primer, Canadian VIGOUR Center, Duke Clinical Research Institute, New York University Clinical Coordinating Center, and PERFUSE Research Institute. Dr Granger reports research grant support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Pfizer, Novartis, Population Health Research Institute, US Food and Drug Administration, and National Heart, Lung, and Blood Institute; and consulting fees from Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, CeleCor Therapeutics, GlaxoSmithKline, Eli Lilly, Medtronic Foundation, Merck & Co, Novartis, Pfizer, Daiichi Sankyo, Rho Pharmaceuticals, Verseon, and Janssen Pharmaceuticals. All current conflicts of interest are listed at <https://dcric.org/about-us/conflict-of-interest/>. Dr Holmes reports no disclosures. Dr Lopes reports grants and personal fees from Bristol Myers Squibb and Pfizer, personal fees from Boehringer Ingelheim and Bayer AG, and grants from Amgen Inc, GlaxoSmithKline, Medtronic PLC, and Sanofi Aventis outside the submitted work. Dr Mehran reports receiving consulting fees from Abbott Vascular, Boston Scientific, Medscape/WebMD, Siemens Medical Solutions, Phillips/Volcano/Spectranetics, Rovi Sciences, Sanofi Italy, Bracco Group, Janssen, and AstraZeneca; grant support, paid to her institution, from Bayer, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals,

OrbusNeich, Osprey Medical, PLC/RenalGuard, and Abbott Vascular; grant support and advisory board fees, paid to her institution, from BMS; fees for serving on a data and safety monitoring board from Watermark Research Funding; advisory fees and lecture fees from Medintelligence (Janssen); and lecture fees from Bayer. Dr Moliterno reports no disclosures. Dr Price reports consulting/advisory board fees and honoraria from Abbott Vascular, AstraZeneca, Boston Scientific, Chiesi USA, Medtronic, and W.L. Gore Medical, and grants (to his institution) from Daiichi Sankyo. Dr Saw has received unrestricted research grant supports from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, National Institutes of Health, AstraZeneca, Abbott Vascular, St Jude Medical, Boston Scientific, and Servier; salary support from Michael Smith Foundation for Health Research; speaker honoraria from AstraZeneca, Abbott Vascular, Boston Scientific, and Bayer; consultancy and advisory board honoraria from AstraZeneca, Boston Scientific, Abbott Vascular, Gore, Abiomed, and Baylis; and proctorship honoraria from Abbott Vascular and Boston Scientific. Dr Tanguay has received consulting fees or honoraria from Abbott, AstraZeneca, Bayer, Biosensors, Bristol Myers Squibb/Pfizer Alliance, Daiichi-Sankyo, Novartis, and Servier; and his institution has received research grants from Abbott Vascular, AstraZeneca, Biosensors, Idorsia, and Novartis.

Supplemental Materials

Data Supplement Table I

REFERENCES

- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757
- Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease: double trouble. *Adv Med Sci*. 2018;63:30–35. doi: 10.1016/j.advm.2017.06.005
- Capodanno D, Angiolillo DJ. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. *Circ Cardiovasc Interv*. 2014;7:113–124. doi: 10.1161/CIRCINTERVENTIONS.113.001150
- Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;74:83–99. doi: 10.1016/j.jacc.2019.05.016
- January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellnor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. *Circulation*. 2019;140:e125–e151. doi: 10.1161/CIR.0000000000000665
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haessler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J*. 2018;39:1330–1393. doi: 10.1093/eurheartj/ehy136
- Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. *J Am Coll Cardiol*. 2018;72:2915–2931. doi: 10.1016/j.jacc.2018.09.057
- Généreux P, Giustino G, Witzensbichler B, Weisz G, Stuckey TD, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. *J Am Coll Cardiol*. 2015;66:1036–1045. doi: 10.1016/j.jacc.2015.06.1323
- Bucheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. *Expert Opin Drug Saf*. 2019;18:1171–1189. doi: 10.1080/14740338.2019.1680637
- Urban P, Mehran R, Collieran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. *Circulation*. 2019;140:240–261. doi: 10.1161/CIRCULATIONAHA.119.040167
- Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective. *Thromb Haemost*. 2011;106:572–584. doi: 10.1160/TH11-04-0262
- Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. *Circ Cardiovasc Interv*. 2011;4:522–534. doi: 10.1161/CIRCINTERVENTIONS.111.965186
- Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective: 2016 update. *Circ Cardiovasc Interv*. 2016;9:e004395. doi: 10.1161/CIRCINTERVENTIONS.116.004395
- Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2018 update. *Circulation*. 2018;138:527–536. doi: 10.1161/CIRCULATIONAHA.118.034722
- Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Janus J, Burton P, van Eickels M, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med*. 2016;375:2423–2434. doi: 10.1056/NEJMoa1611594
- Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, et al; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med*. 2017;377:1513–1524. doi: 10.1056/NEJMoa1708454
- Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med*. 2019;380:1509–1524. doi: 10.1056/NEJMoa1817083
- Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet*. 2019;394:1335–1343. doi: 10.1016/S0140-6736(19)31872-0
- Capodanno D, Angiolillo DJ. Dual antithrombotic therapy for atrial fibrillation and PCI. *Lancet*. 2019;394:1300–1302. doi: 10.1016/S0140-6736(19)31954-3
- Bucheri S, Angiolillo DJ, Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. *Ther Adv Cardiovasc Dis*. 2019;13:1753944719891688. doi: 10.1177/1753944719891688
- Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, Lopes RD, Mehran R, Vranckx P, Angiolillo DJ. Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis. *J Am Heart Assoc*. 2020;9:e017212. doi: 10.1161/JAHA.120.017212
- Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. *JAMA Cardiol*. 2020;5:582–589. doi: 10.1001/jamacardio.2019.6175
- Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. *JAMA Cardiol*. 2019;4:747–755. doi: 10.1001/jamacardio.2019.1880
- Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. *Eur Heart J*. 2018;39:1726–1735a. doi: 10.1093/eurheartj/ehy162

25. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur Heart J*. 2019;40:3757–3767. doi: 10.1093/eurheartj/ehz732
26. Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. *Europace*. 2020;22:538–546. doi: 10.1093/europace/euz345
27. Moon JY, Franchi F, Rollini F, Angiolillo DJ. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. *Prog Cardiovasc Dis*. 2018;60:478–490. doi: 10.1016/j.pcad.2017.12.004
28. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. *Circulation*. 2020;141:781–783. doi: 10.1161/CIRCULATIONAHA.119.044584
29. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, Aronson R, Windecker S, Mehran R, Lopes RD. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. *Circulation*. 2020;141:1618–1627. doi: 10.1161/CIRCULATIONAHA.120.046534
30. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. *Lancet*. 2006;367:1903–1912. doi: 10.1016/S0140-6736(06)68845-4
31. Turagam MK, Velagapudi P, Kar S, Holmes D, Reddy VY, Refaat MM, Di Biase L, Al-Ahmed A, Chung MK, Lewalter T, et al. Cardiovascular therapies targeting left atrial appendage. *J Am Coll Cardiol*. 2018;72:448–463. doi: 10.1016/j.jacc.2018.05.048
32. Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, et al; AUGUSTUS Investigators. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS Trial. *Circulation*. 2019;140:1921–1932. doi: 10.1161/CIRCULATIONAHA.119.043308
33. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haessler KG, Boriani G, Capodanno D, Gilard M, et al; Document Reviewers. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). *Eur Heart J*. 2014;35:3155–3179. doi: 10.1093/eurheartj/ehu298
34. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. *Circulation*. 2009;119:1330–1352. doi: 10.1161/CIRCULATIONAHA.108.191768
35. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. *Lancet*. 2015;386:303–310. doi: 10.1016/S0140-6736(15)60245-8
36. Andò G, Capodanno D. Radial access reduces mortality in patients with acute coronary syndromes: results from an updated trial sequential analysis of randomized trials. *JACC Cardiovasc Interv*. 2016;9:660–670. doi: 10.1016/j.jcin.2015.12.008
37. Angiolillo DJ. Vascular access and antithrombotic therapy in patients with acute coronary syndrome. *Lancet*. 2018;392:801–802. doi: 10.1016/S0140-6736(18)31921-4
38. Stone GW, Witzentichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, et al; HO-RIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med*. 2008;358:2218–2230. doi: 10.1056/NEJMoa0708191
39. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, et al; MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. *N Engl J Med*. 2015;373:997–1009. doi: 10.1056/NEJMoa1507854
40. Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, et al; SYNERGY Trial Investigators. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. *JAMA*. 2005;294:2594–2600. doi: 10.1001/jama.294.20.2594
41. Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. *Ther Adv Cardiovasc Dis*. 2019;13:1753944719893274. doi: 10.1177/1753944719893274
42. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. *N Engl J Med*. 2013;368:1303–1313. doi: 10.1056/NEJMoa1300815
43. Vaduganathan M, Harrington RA, Stone GW, Deliangyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, et al; CHAMPION Investigators. Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol*. 2017;69:176–185. doi: 10.1016/j.jacc.2016.10.055
44. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, et al; LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med*. 2015;373:2038–2047. doi: 10.1056/NEJMoa1503943
45. Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, et al; ONYX ONE Investigators. Polymer-based or polymer-free stents in patients at high bleeding risk. *N Engl J Med*. 2020;382:1208–1218. doi: 10.1056/NEJMoa1910021
46. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein CM. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. *JAMA*. 2018;320:2221–2230. doi: 10.1001/jama.2018.17242
47. Schjerning Olsen AM, McGettigan P, Gerds TA, Fosbøl EL, Olesen JB, Sindet-Pedersen C, Staerk L, Hansen ML, Pallisgaard JL, Køber L, et al. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. *Eur Heart J Cardiovasc Pharmacother*. 2020;6:292–300. doi: 10.1093/ehjcvp/pvz069
48. Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. *Nat Rev Cardiol*. 2018;15:480–496. doi: 10.1038/s41569-018-0049-1
49. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, et al. International expert consensus on switching platelet P2Y₁₂ receptor-inhibiting therapies. *Circulation*. 2017;136:1955–1975. doi: 10.1161/CIRCULATIONAHA.117.031164
50. Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. *Lancet*. 2017;389:987–989. doi: 10.1016/S0140-6736(17)30591-3
51. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, et al; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. 2017;389:1025–1034. doi: 10.1016/S0140-6736(17)30397-5
52. Costa F, Valgimigli M, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Lip GYH, Oldgren J, Cannon CP. Triple antithrombotic therapy with warfarin or dual therapy with dabigatran according to the PRECISE-DAPT score in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the RE-DUAL PCI trial. *Circulation*. 2019;140:A13474. doi: 10.1093/ehjcvp/pvaa135
53. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, et al; PRECISE-DAPT Study Investigators. Dual antiplatelet therapy duration based on ischemic and bleeding

risks after coronary stenting. *J Am Coll Cardiol*. 2019;73:741–754. doi: 10.1016/j.jacc.2018.11.048

54. Ueki Y, Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, Gragnano F, Gargiulo G, Siontis GCM, Praz F, et al. Validation of bleeding risk criteria (ARC-HBR) in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. *EuroIntervention*. 2020;16:371–379. doi: 10.4244/EIJ-D-20-00052
55. Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, Stefanini GG, Angiolillo DJ, Capodanno D, Urban P, et al. Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. *J Am Coll Cardiol*. 2020;75:2711–2722. doi: 10.1016/j.jacc.2020.03.070
56. Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. *Eur Heart J*. 2019;40:1553–1562. doi: 10.1093/eurheartj/ehz059
57. Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, et al. Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial. *Circ Cardiovasc Interv*. 2020;13:e008349. doi: 10.1161/CIRCINTERVENTIONS.119.008349
58. Kerneis M, Gibson CM, Chi G, Mehran R, Alkhalaf F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, et al. Effect of procedure and coronary lesion characteristics on clinical outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI Trial. *JACC Cardiovasc Interv*. 2018;11:626–634. doi: 10.1016/j.jcin.2017.11.009
59. Vranckx P, Valgimigli M, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimnitz PE, Smolnik R, et al. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. *Eur Heart J*. 2020;41:4497–4504. doi: 10.1093/eurheartj/ehaa617
60. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. *Nat Rev Cardiol*. 2015;12:30–47. doi: 10.1038/nrcardio.2014.156
61. Tovar Forero MN, Zanchin T, Masdjedi K, van Zandvoort JC, Kardys I, Zijlstra F, Häner J, Windecker S, Van Mieghem NM, Räber L, et al. Incidence and predictors of outcomes after a first definite coronary stent thrombosis. *EuroIntervention*. 2020;16:e344–e350. doi: 10.4244/EIJ-D-19-00219
62. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. *J Am Coll Cardiol*. 2016;68:1851–1864. doi: 10.1016/j.jacc.2016.07.760
63. Dangas G, Baber U, Sharma S, Giustino G, Mehta S, Cohen DJ, Angiolillo DJ, Sartori S, Chandiramani R, Briguori C, et al. Ticagrelor with or without aspirin after complex PCI. *J Am Coll Cardiol*. 2020;75:2414–2424. doi: 10.1016/j.jacc.2020.03.011
64. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–477. doi: 10.1093/eurheartj/ehz425
65. Franchi F, Rollini F. Switching oral anticoagulant therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv*. 2019;12:2342–2345. doi: 10.1016/j.jcin.2019.10.017
66. Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, et al. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). *J Am Heart Assoc*. 2018;7:e007633. doi: 10.1161/JAHA.117.007633
67. Yu HT, Yang PS, Jang E, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Lip GYH, Joung B. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. *J Am Heart Assoc*. 2020;9:e014177. doi: 10.1161/JAHA.119.014177
68. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, Sirbu V, Bass TA, Della Rovere F, Gavazzi A, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. *Am J Cardiol*. 2008;102:1618–1623. doi: 10.1016/j.amjcard.2008.08.021
69. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eckels M, Lip GY, Cohen M, Husted S, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). *Am Heart J*. 2015;169:472–478. e5. doi: 10.1016/j.ahj.2014.12.006
70. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet*. 2009;374:29–38. doi: 10.1016/S0140-6736(09)60738-8
71. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001–2015. doi: 10.1056/NEJMoa0706482
72. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045–1057. doi: 10.1056/NEJMoa0904327
73. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, et al; THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. *N Engl J Med*. 2019;381:1309–1320. doi: 10.1056/NEJMoa1908077
74. Sarafoff N, Martischinig A, Wealer J, Mayer K, Mehili J, Sibbing D, Kastrati A. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. *J Am Coll Cardiol*. 2013;61:2060–2066. doi: 10.1016/j.jacc.2013.02.036
75. Mehran R, Kalkman DN, Angiolillo DJ. Atrial fibrillation, with ACS and PCI: walking a tightrope. *Eur Heart J*. 2019;40:1563–1566. doi: 10.1093/eurheartj/ehz192
76. Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED, et al. Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease (STEEL-PCI). *Circulation*. 2018;138:1290–300. doi: 10.1161/CIRCULATIONAHA.118.034790
77. Franchi F, Rollini F, Been L, Briceno M, Maaliki N, Wali M, Rivas A, Pineda AM, Suryadevara S, Soffer D, et al. Pharmacodynamic and pharmacokinetic effects of a low maintenance dose ticagrelor regimen versus standard dose clopidogrel in diabetes mellitus patients without previous major cardiovascular events undergoing elective percutaneous coronary intervention: the OPTIMUS-6 study. *Circulation*. 2020;142:1500–1502. doi: 10.1161/CIRCULATIONAHA.120.048770
78. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. *JACC Cardiovasc Interv*. 2019;12:1521–1537. doi: 10.1016/j.jcin.2019.03.034
79. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, et al; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet*. 2013;381:1107–1115. doi: 10.1016/S0140-6736(12)62177-1
80. Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sørensen R, Køber L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. *Circulation*. 2014;129:1577–1585. doi: 10.1161/CIRCULATIONAHA.113.004834
81. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, Goto K, Nakai K, Ogawa H, Kobori A, et al; OAC-ALONE Study Investigators. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. *Circulation*. 2019;139:604–616. doi: 10.1161/CIRCULATIONAHA.118.036768
82. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, et al; AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. *N Engl J Med*. 2019;381:1103–1113. doi: 10.1056/NEJMoa1904143